Center for Global Health Faculty

Associate Professor

Academic Degrees

• MD

Departmental Affiliation

• Name:

  International Health

  Affiliation Type:

  Primary

  Division:

  Global Disease Epidemiology and Control

Departmental Address

Contact Information

Email:

adurbin+jhsph.edu

Phone:

410-614-4736

Fax:

410-502-6898

Link:

SciVal Experts Research Profile

Research and Professional Experience

My research involves the evaluation of experimental vaccines in human clinical trials. At the Center for Immunization Research, we have conducted numerous clinical trials of many different pediatric and adult candidate vaccines. These trials have included vaccines against HIV, hepatitis C, human papilloma virus, influenza, rotavirus, respiratory syncytial virus, dengue virus, and malaria. I am primarily interested in vaccines against dengue viruses and malaria have a very active dengue and malaria vaccine programs here at the Center for Immunization Research. We haven conducted numerous Phase I live attenuated dengue vaccine trials with the ultimate goal of identifying suitable monovalent vaccine viruses for inclusion in a tetravalent dengue vaccine.  In addition, we have conducted many Phase I malaria vaccine trials at our clinical site in Washington DC.  An important interest of mine is studying the immunopathogenesis of dengue infection and disease. We hope to better understand the viral, host, and immunologic factors causing severe dengue illness by extensively characterizing the cellular and humoral responses of volunteers to live attenuated dengue virus vaccines. In addition to our clinical studies, my laboratory is also developing an animal model of dengue using rhesus macaques.

Keywords

International Health, Dengue, Malaria, Vaccines

Honors and Awards

2005: National Institutes of Health Merit Award for outstanding basic and translational research in developing vaccines for the prevention of respiratory virus and flavivirus diseases

Selected Publications

Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010;338:129-43

Ellis RD, Martin LB, Shaffer D, Long CA, Kazutoyo M, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1₄₂-C1/alhydrogel with and without CPG 7909 in malaria naïve adults.  PLos One 2010;5(1):e8787

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, and Schmidt AC.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4D30-4995 in healhty adult volunteers. Am J Trop Med Hyg. 2009; 81(5):834-41.

Blaney JE, Jr., Durbin AP, Murphy BR and Whitehead SS. Targeted mutagenesis as a rational approach to dengue virus vaccine development. Curr Top Microbiol Immunol 2010;338:145-58

Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010;338:129-43

Durbin AP, Setse R, Omer SB, et al. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine 2009; 27:6143-47

Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, and Durbin AP.  A Phase 1 study of the blood-stage malaria vaccine 

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, and Whitehead SS. Phase I Study of the Safety and Immunogenicity of rDEN4?30-200,201 a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4. Am J Trop Med Hyg 2008;79(5):678.

Durbin, A. P., M. J. Vargas, K. Wanionek, S. N. Hammond, A. Gordon, C. Rocha, A. Balmaseda, and E. Harris. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 2008;376:429-35.

Wu Y, Ellis RD, Shaffer D, Fontes, E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, and Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008;3:e2636.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, et al. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008 Feb 13;26(7):882-90.

Whitehead SS, Blaney JE, Durbin AP and Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007;5:518-28.

Durbin, AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, and Whitehead SS. 2006. rDEN2/4Delta30(ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults. Hum Vaccin 2(6):255-260.

Durbin, AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar Wanionek K, Murphy BR, and Whitehead SS. 2006. The live attenuated dengue serotype 1 vaccine rDEN1?30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccin 2(4):167-173.

Blaney JE, Jr., Durbin AP, Murphy BR and Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006;19:10-32

Malkin, EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orbutt A, Awkal M, Zhou H, Want J, Stowers AW, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. Phase 1 clinical trial of apical membrane antigen 1 (AMA1): An asexual blood stage vaccine for Plasmodium flaciparum malaria. Infect. Immun. 2005:73(6);3677-3685

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J,Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers AW, Miller LH, Saul A. Phase 1 Vaccine Trial of Pvs25H: A Transmission Blocking Vaccine for Plasmodium vivax Malaria. Vaccine 2005:23(24):3131-3138.

Durbin, AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr., Thumar B, Murphy BR, and Karron RA. rDEN4?30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005:191;710-718

Durbin AP, Karron RA, Thumar B, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. A live attenuated dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in the 3´ untranslated region is highly attenuated and immunogenic in humans. Am J Trop Med Hyg, 2001;65:405-413.

Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR. A live attenuated dengue-4 virus vaccine candidate with a 30 base pair deletion in its 3´ untranslated region has restricted capacity for dissemination in mosquitoes and is not transmitted from vaccinees to mosquitoes. Am J Trop Med Hyg, 2001;65:414-419.